These results indicated that VISTA+ TAMs were associated with reduced efficacy of PD‐1 inhibitor camrelizumab on promotion of tumour cell apoptosis and reactivation of CD8+ T‐cell‐effective function. This evidence concerns the gene CD8A and neoplasm.